THE DEAL, AT A GLANCE
From the announcementBrainChild Bio
01Who is involvedBacked by the phase 1 BrainChild-03 clinical trial (NCT04185038), which is being carried out by Seattle Children’s, BrainChild’s academic partnerFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedBrainChild Bio raised $116M Series A, announced 2026-09-08From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersBrainChild Bio's $116 Million Series A funds a launch around a commercial candidate for pediatric DIPG ready for a pivotal trial.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
BrainChild Bio · Financing Record
Explore source-linked visual explanations for BrainChild Bio. Unsupported claims are withheld while source review continues.
Record 11870 · Recorded date: 2026-09-08
Explore company records →